Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002.
The study, conducted in healthy volunteers, evaluated the safety and pharmacokinetics of the drug. Interim results showed a half-life of 75-80 days, supporting the potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. ORKA-002 was well tolerated at all dose levels, with no severe or serious treatment-emergent adverse events reported.
Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 in psoriasis and the second half of 2026 in hidradenitis suppurativa.
Meanwhile, a Phase 2b study of ORKA-001 dubbed EVERLAST-B is underway with data expected in 2027.
On Friday, Oruka shares closed at $27.86, up 5.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.